Additionally, studies exploring the role of GLP-1 receptor polymorphisms and neurochemical pathways may help clarify individual differences in response to therapy
This article examines the available glutathione options, their mechanisms, and how they fit within the broader context of fatty liver care under UK clinical guidance
Sleep and behavior problems among preschoolers
The dose of the drug can be increased to 1 mg, 2 mg, or 4 mg after 4 weeks, depending on the patient's response
The article names phentermine and phendimetrazine as sympathomimetics acting through overlapping appetite pathways, and distinguishes them from direct GLP-1 agonists such as liraglutide and semaglutide
In a Phase II study, the CD19-targeting CAR-T mivocabtagene autoleucel demonstrated significant improvement in individuals with stiff person syndrome, with a 46% median improvement in a timed 25-foot walk at week 16 and sustained B-cell depletion without high-grade cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome